Searched for: subject%3A%22Lipoproteins%22
(1 - 20 of 269)

Pages

Sleep duration and lipid metabolism in patients with diabetes mellitus
Sleep duration and lipid metabolism in patients with diabetes mellitus: from the POWER2DM study
A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
High fat diet-induced obesity prolongs critical stages of the spermatogenic cycle in a Ldlr-/-.Leiden mouse model
High fat diet-induced obesity prolongs critical stages of the spermatogenic cycle in a Ldlr-/-.Leiden mouse model
Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans
Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
Efficacy, safety and novel targets in cardiovascular disease
Efficacy, safety and novel targets in cardiovascular disease: advanced applications in APOE*3-Leiden.CETP mice
Dose effects of ammonium perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP mice
Dose effects of ammonium perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP mice
Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis
Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis
Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
Ranges of phenotypic flexibility in healthy subjects
Ranges of phenotypic flexibility in healthy subjects
A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice
A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice
Comment on
Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46-54
Weight loss predictability by plasma metabolic signatures in adults with obesity and morbid obesity of the DiOGenes study
Weight loss predictability by plasma metabolic signatures in adults with obesity and morbid obesity of the DiOGenes study
The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses
The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes
Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes
Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development
Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development
Replacement of Dietary Saturated Fat by PUFA-Rich Pumpkin Seed Oil Attenuates Non-Alcoholic Fatty Liver Disease and Atherosclerosis Development, with Additional Health Effects of Virgin over Refined Oil
Replacement of Dietary Saturated Fat by PUFA-Rich Pumpkin Seed Oil Attenuates Non-Alcoholic Fatty Liver Disease and Atherosclerosis Development, with Additional Health Effects of Virgin over Refined Oil
Anacetrapib reduces (V)LDL-cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
Anacetrapib reduces (V)LDL-cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia
Searched for: subject%3A%22Lipoproteins%22
(1 - 20 of 269)

Pages